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Abstract: Acute myeloid leukemia with biallelic mutation of CEBPA(CEBPA-
dm AML) is a distinct good prognosis entity recognized by WHO 2016 
classification. However, testing for CEBPA mutation is challenging, due 
to the intrinsic characteristics of the mutation itself. Indeed, 
molecular analysis cannot be performed with NGS technique and requires 
Sanger sequencing. The association of recurrent mutations or 
translocations with specific immunophenotypic patterns has been already 
reported in other AML subtypes. The aim of this study was the development 
of a specific cytofluorimetric score (CEBPA-dm score), in order to 
distinguish patients who are unlikely to harbor the mutation.  To this 
end, the correlation of CEBPA-dm score with the presence of the mutation 
was analyzed in 50 consecutive AML patients with normal karyotype and 
without NPM1 mutation (that is mutually exclusive with CEBPA mutation). 
One point each was assigned for expression of HLA DR, CD7, CD13, CD15, 
CD33, CD34 and one point for lack of expression of CD14. 
OS was not influenced by sex, age and CEBPA-dm score. Multivariate OS 
analysis showed that CEBPA-dm (p<0.02) and FLT3-ITD (p<0.01) were the 
strongest independent predictors of OS. With a high negative predictive 
value (100%), CEBPA-dm score < 6 was able to identify patients who are 
unlikely to have the mutation. Therefore, the application of this simple 
score might optimize the use of expensive and time-consuming diagnostic 






A complete and updated molecular evaluation of patients with Acute Myeloid Leukemia is complex, time 
consuming and expensive and cannot be routinely performed in many hematological centers. Biallelic 
mutation of CCAAT/enhancer binding protein A gene (CEBPA-dm) defines a distinct AML subtype of 2016 
WHO classification which has been assigned a favorable prognosis by European Leukemia Net (ELN). The 
identification of CEBPA-dm  still requires Sanger sequencing, that is difficult to perform, due to the great 
variability of mutations, the lack of hot spots and the presence of single nucleotide mutations. Previous 
reports suggested the use of immunophenotypic aberrations to identify patients harbouring the mutation. 
Analyzing a selected cohort of AML patients without cytogenetic aberrations or NPM1 mutation we 
propose a new seven points immunophenotipic score, based  only on surface antigen expression (CEBPA-
dm score). Our seven-points score was able to identify patients harboring CEBPA-dm, but proved most 
useful in disclosing AML patients with no probability of having CEBPA-dm. Our study suggests that patients 
with a CEBPA-dm score ≥ 6 should immediately undergo Sanger sequencing for CEBPA-dm, whereas in the 
other patients this complex evaluation might be delayed (or even omitted?) due to very low probability of 
finding the mutation. This could optimize prognostic stratification work up by giving the right priority to the 
sample evaluation. For these reasons we are convinced that our study deserves to be published in your 
Journal. 
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First of all, we wish to thank the Editor for considering our paper for publication in Leukemia Research and 
the Rewievers for the insightful comments. 
Rewiever #2: 
The authors have defined the flow cytometric characteristics of AML patients with CEBPA-dm genotype, a 
good prognostic group.  This provides valuable clinical information that can guide the molecular workup of 
such patients and consequently therapeutic decisions. Additional suggestions: 
1. Flow markers can be dim, moderate, or bright and may be present an all or only a subset of the blasts. 
The authors might state whether partial or dim expression of a marker, e.g. CD7, was still given a point 
in their scoring system. Also, consider showing representative flow data for one patient. 
We added in method section details on definition of positive markers in our scoring system. Figure 1 with 
flow cytometry data from a representative case has been provided.  
2. CEBPA mutations are classified as N-terminal (N) and C-terminal (C), with N+C having better prognosis 
than C+C or N+N.  For their 9 CEBPA-dm patients, the authors should state the number in each 
category (NC, CC, NN) and how many of these got 7 points and how many 6 points. 
We included in the results section details on specific combination of mutations in patients with biallelic 
CEBPA mutations providing also correlation with their CEBPA score. 
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 AML with CEBPA-dm is a distinct entity with an overall favorable outcome. 
 The evaluation of CEBPA-dm requires difficult and time consuming Sanger sequencing. 
 CEBPA-dm AML has a peculiar immunophenotypic signature. 
 The presence or the absence of CEBPA-dm can be predicted with our IF score. 
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Acute myeloid leukemia with biallelic mutation of CEBPA (CEBPA-dm AML) is a distinct good 
prognosis entity recognized by WHO 2016 classification. However, testing for CEBPA mutation is 
challenging, due to the intrinsic characteristics of the mutation itself. Indeed, molecular analysis 
cannot be performed with NGS technique and requires Sanger sequencing. The association of 
recurrent mutations or translocations with specific immunophenotypic patterns has been already 
reported in other AML subtypes. The aim of this study was the development of a specific 
cytofluorimetric score (CEBPA-dm score), in order to distinguish patients who are unlikely to 
harbor the mutation.  To this end, the correlation of CEBPA-dm score with the presence of the 
mutation was analyzed in 50 consecutive AML patients with normal karyotype and without NPM1 
mutation (that is mutually exclusive with CEBPA mutation). One point each was assigned for 
expression of HLA DR, CD7, CD13, CD15, CD33, CD34 and one point for lack of expression of 
CD14. 
OS was not influenced by sex, age and CEBPA-dm score. Multivariate OS analysis showed that 
CEBPA-dm (p<0.02) and FLT3-ITD (p<0.01) were the strongest independent predictors of OS. 
With a high negative predictive value (100%), CEBPA-dm score < 6 was able to identify patients 
who are unlikely to have the mutation. Therefore, the application of this simple score might 
optimize the use of expensive and time-consuming diagnostic and prognostic assessment in the 
baseline work up of AML patients. 
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CCAAT/enhancer binding protein alpha gene (CEBPA) encodes for a transcription factor that is 
required for myeloid precursor differentiation. [1-4] CEBPA mutations are observed in 10 to 18% of 
AML patients. [5] Biallelic mutations occur in half of the cases and play a central role in the 
development of the disease. [6-10] AML with biallelic mutations of CEBPA (CEBPA-dm) is now 
considered a distinct entity by the WHO 2016 classification. [11] The presence of CEBPA-dm 
mutually excludes the presence of other recurrent genetic abnormalities, such as NPM1 mutation, 
and is unfrequently associated with FLT3-ITD mutation. [12,13] 
European Leukemia Net (ELN) 2017 includes CEBPA-dm AML into the good prognosis subgroup 
[14,15] so that allogeneic stem cells transplantation in first complete remission is not recommended. 
[16] 
The assessment of CEBPA gene mutations by Sanger sequencing is challenging due to the great 
variability of molecular alterations, the lack of hot spots and the presence of single nucleotide 
mutations. [17,18-21] Detecting CEBPA mutations by Sanger sequencing is therefore expensive and 
time consuming and should be performed only in experienced centers [18, 19]. Moreover, for the 
same technical reasons, Next Generation Sequencing (NGS) is not optimal for the study of CEBPA-
dm [17,18-21]. A novel NGS approach might overcome some of these problems, but the technique 
is still in an early development phase and needs to be validated and standardized [22]. 
Immunophenotypic analysis with multi-parametric flow-cytometry (IF) is mandatory in the 
diagnostic work-up of AML, [16,23] allowing the identification of the blast cells lineage and 
leukemia-associated phenotypes. [24,25] In AML, some recurrent chromosomal or molecular 
abnormalities have been shown to be associated with specific immunophenotypic patterns, as 
reported for patients with t(8;21) and with mutation of NPM. [26,27] Recently, correlations between 
IF features and presence of CEBPA-dm have been described. [26-30]  
The primary aim of our study was to develop a new IF-score, based only on combined surface 
antigen expression, in order to assess its correlation with the presence of CEBPA-dm.  As accessory 
end points the impact of IF-score on disease outcome was evaluated and compared with other 
clinical and molecular variables. 
 
2. Material and Methods 
2.1 Patients 
 
One-hundred consecutive younger (<60 yrs), de-novo AML patients, treated between January 2006 
and January 2016, with available cytofluorimetric, cytogenetic and molecular assessment at 
diagnosis were included in the present study. All patients received fludarabine-high dose 
cytarabine-idarubicine intensive induction followed by a risk-adapted consolidation strategy. [25,31] 
Molecular assessment included RT-PCR for NPM1 mutation, FLT3-ITD and CEBPA. All patients 
with cytogenetic abnormalities and/or with NPM1 mutation were excluded from the analysis, as 
those abnormalities are not found in patients with CEBPA-dm. [17, 32, 33]  
Fifty patients were therefore included in the study. Median age at diagnosis was 51.5 years (range 
19-60 years); 27 patients (54%) were male; median WBC count at diagnosis was 14400/µl (range 1-
380000/ µl), high allelic burden FLT3-ITD mutation was found in 6 patients (12%), CEBPA-dm in 9 
patients (18%). ELN 2017 risk assessment [15] was favorable or intermediate in 44 patients (88%) 
and high in 6 (12%). 
 
2.2 Statistical Methods 
 
Continuous variables were compared using Student’s T test or, where necessary, Wilcoxon’s Rank 
test. Dichotomous variables were compared using the Chi-square test or, where necessary, Fisher’s 
exact test.  
Survival curves were built using the Kaplan Meier method, and univariate survival analysis was 
performed using the Log-rank test. A landmark analysis was performed at day 90 for DFS 
evaluation, both in the whole cohort of patients and in patients undergoing allo-BMT in CR1, 
including all patients alive and achieving CR after one or two induction cycles. A Cox Proportional 
Hazard Model was built for multivariate survival analysis, including only the variables that 
respected proportional risk assumption. All two-tailed p-values <0.05 were considered statistically 
significant. [34]  
All analysis has been performed on IBM SPSS® v22 running on Debian (Linux) operating system. 
 
2.3 Molecular analysis 
 
NPM1 mutation (NPM1-A, B and D mutation) was measured using Muta Quant Kit Ipsogen from 
Qiagen. [35] 
FLT3-ITD allelic burden was determined as ratio of Time PCR were performed on DNA Engine 
Opticon 2 - BIORAD. FLT3-ITD mutations were searched using polymerase chain reaction (PCR 
the area under the curve “FLT3-ITD” divided by AUC “FLT3-wild type” (low allelic ratio <0.5; 
high allelic ratio >0.5). [36,37] 
CEBPA-dm were detected by genomic DNA PCR and direct sequencing. The primer sets are those 
designed by Pabst et al. [6] There are three overlapping primer pairs were used to amplify the entire 
coding region of human CEBPA: CEBPA AF-TCGCCATGCCGGGAGAACTCTAAC, CEBPA 
ARAGCTGCTTGGCTTCATCCTCCT (548bp); CEBPA BF-CCGCTGGTGATCAAGCAGGA, 
CEBPA BR-CCGGTACTCGTTGCTGTTCT (390bp); CEBPA 
CFCAAGGCCAAGAAGTCGGTGGACA, CEBPA CR-CACGGTCTGGGCAAGCCTCGAGAT 
(356bp). PCR reactions were made in a final volume of 50 μL containing genomic DNA (300 ng), 
KCl (50 mmol/L), Tris-HCl (20 mmol/L, pH 8.4), MgCl2 (2.5 mmol/L), 5 volume % DMSO, 
primers (2 mmol/L of each), nucleotides (0.1 mmol/L of each), and Taq DNA polymerase (1U). 
PCR conditions were 94°C for 45 seconds, 62°C for 45 seconds and 72°C for 45 seconds for 45 
cycles, with a final step for 10 minutes at 72°C. PCR products were sequenced using BigDye. 
Terminator Cycle Sequencing Kit o v1.1 kit (Applied Biosystems) on ABI 3730 Genetic Analyzer 
(Applied Biosystems). 
 
2.4 Flow cytometry  
  
Erythrocyte-lysed whole BM samples obtained at diagnosis were analyzed with a broad panel of 
monoclonal antibodies to define lineage according to WHO classification and to identify the most 
relevant aberrations described in blasts (leukemia-associated immunophenotype (LAP), as 
described elsewhere. [23,24] A broad combination of monoclonal antibodies in eight color staining 
(FITC, fluorescein isotiocyanate/PE phycoerythrin/ PerCP-Cy™5.5, peridinin-chlorophyll proteins-
cychrome 5.5 /APC, allophycocyanin/ BD™ APC-H7, allophycocyanin/ BD Horizon V450™ / BD 
Horizon V500™) were used at diagnosis. An expression on more than 25% of leukemic cells was 
considered as positive. All antibodies were purchased from BD Biosciences (San Jose, CA, USA) 
except for Polyclonal Rabbit Anti-Human lysozyme from DAKO (Milan, Italy). At least two 
antibody combinations found relevant at diagnosis, were used to track residual leukemic cells 
during follow up. Data were acquired using BD FACSCAnto II Flow Cytometer (BD Bioscience, 
San Jose, CA). Instrument performance over time was assessed by BDTM Cytometer Setup and 
Tracking Beads. 
We define a positive expression of an antigen if expressed >20%. The antigens were considered 
expressed if present in at least one of the leukemic populations.  
Basing on previous reports on IF features of CEBPA-dm AML, a comprehensive flow-cytometry-
based CEBPA-dm score was created, assigning one point each for expression of HLA DR, CD7, 






CEBPA-dm score was 7 in 2 patients, (4%), 6 in 16 (32%), 5 in 22 (44%), 4 in 6 (24%), 3 in 2 (4%), 
and 2 in 2 cases (4%). The flow cytometry data from a representative case of a patient with a 
CEBPA-dm score of 7/7 is depicted in Fig.1  
A score of 6 or greater was significantly correlated with the presence of CEBPA-dm (p<0.05), 
whereas no CEBPA-dm was recorded among patients with a score less than 6. 
The positive predictive value (PPV) for a score greater than 5 was 9/18 (50%), whereas the negative 
predictive value (NPV) for a score lower than 6 was 100% (Tab 1). 
Four out of the 6 patients with a CEBPA score of 6 with a positive CD7 had CEBPA-dm. The PPV 
for a score >5 including the CD7 expression was 75%. In this series, 60-day mortality was 6%. 
Main causes of early death were uncontrolled infections or bleedings. In surviving patients, CR rate 
was 40/47 (85%). 
Among 9 patients with biallelic mutation, 6, 2 and 1 patients had N+C, C+C, and N+N mutations, 
respectively. The two patients with a CEBPA score of 7/7 had a N+C and a C+C mutation, whereas 
the patients with a score of 6/7 had a N+C, C+C and N+N in 5, 1 and 1 cases, respectively.   
None of the analyzed variables significantly correlated with complete response (CR) probability, 
although CEBPA-dm patients and patients with CEBPA-dm score  6 had a trend toward higher CR 
rate (Tab. 2). 
With a median follow-up of 62 months (IC 95%: 39.89-84.10 months), 3-year Overall Survival (OS) 
was 54.9% (median not reached, Fig. 2). 
Patients with CEBPA-dm had better outcome if compared to unmutated patients (3-year OS was 
74.1% and 51.5% in patients with or without CEBPA-dm, respectively, p<0.02, Fig. 3).  
Patients with FLT3-ITD had a shorter survival (3-year OS was 16.7% and 64.2% in patients with or 
without FLT3-ITD mutation, respectively p <0.003, Fig 4).  
WBC count at diagnosis only exerted a borderline influence on OS (3-year OS was 37.8 and 66.7%, 
in patients with WBC at diagnosis higher or lower than 30000/µl, respectively, p=0.057). OS was 
not influenced by sex, age and CEBPA-dm score.  
Multivariate OS analysis showed that CEBPA-dm (p<0.02) and FLT3-ITD (p<0.01) were the 
strongest independent predictors of OS. Detailed analysis of OS is provided in Tab. 3. 
 
4. Discussion  
 
 
In some AML subgroups, the correlation between cytogenetic and molecular alterations and IF has 
been reported, [29,31]. Few studies have specifically correlated immunophenotypic features with 
CEBPA mutations. [17,26,28,30] 
In this paper, we combined the single phenotypic aberrations, already reported in patients with 
CEBPA-dm, and developed a simple 7-antigens IF score correlating with the presence of CEBPA-dm 
in a cohort of cytogenetically normal, de novo AML patients. A score of 7 had a very high 
sensitivity in identifying CEPBA-dm but most patients with CEBPA-dm had a score of 6. Our data 
seem to indicate that CD7 expression is more important than other IF markers, as patients with a 
score of 6 including CD7 expression had an increased probability of harboring CEBPA-dm. This 
observation is consistent with previous reports showing that biallelic CEBPA mutation by itself 
could lead to aberrant expression of CD7 in myeloid cells [17,28,38].  
Most importantly, no patients with a CEBPA-dm score lower than 6 had the mutation (NPV 100%). 
Early studies mainly proposed the use of CEBPA-dm associated immunophenotypic features for 
subsequent minimal residual disease evaluation. [7, 8] More recently Mannelli et al. disclosed a 
strong positive correlation between a combination of six antigens and a particular side scatter value 
with the presence of CEBPA-dm and suggested the use of IF analysis to promptly identify patients 
harboring the mutation [28]. Our seven-points score, albeit the small number of patients included in 
our series, was able to identify patients harboring CEBPA-dm but proved most useful in disclosing 
AML patients with no probability of having CEBPA-dm. Moreover, a combination based only on 
antigen expression may potentially improve the reproducibility. A screening strategy based on 
CEBPA-dm score, thanks to its very high NPV, has a very low risk of missing AML patients with 
CEBPA-dm and may be helpful in centers where the molecular screening for CEBPA-dm cannot be 
promptly performed in all newly diagnosed patients. Furthermore, as IF is routinely performed at 
diagnosis, the application of the CEBPA-dm score will not increase cost or time expenditure. 
Differently from what was described in other AML subtypes, [23,29,39] the CEBPA-dm score alone 
did not show prognostic significance in our study cohort. Conversely, our results underline that the 
presence of molecular aberrations such as FLT3-ITD mutation or CEBPA-dm are more relevant than 
the combined expression of surface markers.  
Overall, our study suggests that patients with a CEBPA-dm score ≥ 6 should immediately undergo 
Sanger sequencing for CEBPA-dm, whereas in the other patients this complex evaluation might be 
delayed (or even omitted?) due to very low probability of finding the mutation. This could optimize 
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CEBPA-dm Score Number pts. CEBPA MUTATED 
7 2 (4%) 2/2 (100%) 
6 16 (32%) 7/16 (43.8%) 
5 22 (44%) 0 
4 6 (12%) 0 
3 2 (4%) 0 
2 2 (4%) 0 
 
  
 CR-RATE p 
ALL PATIENTS 40/47  
CEBPA-dm 10/10 (100%) 
0.318 
CEBPA wild type 30/37 (80.1%) 
FLT3-ITD -negative 36/42 (85.7%) 
0.571 
FLT3-ITD -positive 4/5 (80.0%) 
CEBPA-dm score ≥ 6 16/17 (94.1%) 
0.396 
CEBPA-dm score < 6 24/30 (80.0%) 
Sex -male 22/26 (84.6%) 
1.00 
Sex -female 18/21 (85.7%) 
Age < 45 12/15 (80.0%) 
0.664 
Age > 45 28/32 (87.5%) 
WBC < 30000/µl 30/34 (88.2%) 
0.377 
WBC > 30000/µl 10/13 (76.9%) 
 
  






ALL PATIENTS NR 54.9 - 
CEBPA-dm NR 74.1% 0.015 
(0.015) CEBPA - wild type NR 51.5% 
FLT3-ITD -negative NR 64.2% 0.002 
(0.005) FLT3-ITD -positive 6 16.7% 
CEBPA score  6 NR 58.8% 0.700 
(-) CEBPA score < 6 NR 55.9% 
Sex male NR 61.2% 0.397 
(-) Sex female 38 54.9% 
Age < 45 yo NR 60.8% 0.469 
(-) Age > 45 yo NR 57.1% 
WBC < 30000/µl NR 66.7% 0.057 
(0.165) WBC > 30000/µl 15 37.8% 
 
Figures Legends 
Figure 1: Flow cytometry data from a patient with CEBPA-dm score of 7/7 
Figure 2: Overall Survival in all patients 
Figure 3: Overall Survival according to biallelic CEBPA mutation status 




Table 1: Correlation between CEBPA-dm score and biallelic CEBPA mutation 
Table 2: CR probability in evaluable patients 
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